| Time to send to reviewers | 2 weeks |
|---|---|
| Time to decision with review | 65 days |
| Time to publication | 6 months |
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 4
Evaluation of serum HMGB-1 and serum P-glycoprotein levels in epileptic patients: Associations with clinical features, seizure patterns, and drug resistance
1 Istanbul Medipol University, School of Medicine, Institute of Health Science, Department of Medical Pharmacology, Istanbul, Türkiye2 Istanbul Medipol University, Research Institute for Health Sciences and Technologies (SABITA), Istanbul, Türkiye
3 Umraniye Training and Research Hospital, Department of Neurology, Istanbul, Türkiye
4 Haydarpasa Numune Training and Research Hospital, Department of Neurology, Istanbul, Türkiye
5 Istanbul Medipol University, School of Medicine, Department of Medical Statistics and Medical Informatics, Istanbul, Türkiye
DOI : 10.23893/1307-2080.APS6348 Viewed : 77 - Downloaded : 26 This study aimed to evaluate the association of serum HMGB-1 and serum P-gp levels with clinical characteristics, seizure patterns, and drug resistance in patients with epilepsy. Patients were divided into monotherapy (n=40) and polytherapy (n=40) groups, and their serum HMGB-1 and serum P-gp levels were analysed using the ELISA technique. In the multinomial logistic regression model, serum P-gp levels were significantly higher in the polytherapy group compared to the healthy control group (p=0.021). Additionally, to the best of our knowledge, this is the first study to analyse the correlation between serum HMGB-1 and serum P-gp levels. In this study, a moderate positive correlation was found between serum HMGB-1 and serum P-gp levels in the monotherapy group of epilepsy patients. Keywords : drug resistance, epilepsy, HMGB-1, P-glycoprotein, serum